[1] S. Oliveto, M. Mancino, N. Manfrini and S. Biffo. Role of microRNAs in translation regulation and cancer. World J. Biol. Chem. 8(1), pp. 45-56. 2017. DOI: 10.4331/wjbc.v8.i1.45.
[2] M. Garofalo and C. M. Croce. Role of microRNAs in maintaining cancer stem cells. Adv. Drug Deliv. Rev. 81pp. 53-61. 2015. DOI: 10.1016/j.addr.2014.11.014.
[3] C. H. Liu, J. Ampuero, A. Gil-Gomez, R. Montero-Vallejo, A. Rojas, R. Munoz-Hernandez, R. Gallego-Duran and M. Romero-Gomez. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Hepatol. 69(6), pp. 1335-1348. 2018. DOI: S0168-8278(18)32289-X.
[4] X. Wang, Z. Liao, Z. Bai, Y. He, J. Duan and L. Wei. MiR-93-5p promotes cell proliferation through down-regulating PPARGC1A in hepatocellular carcinoma cells by bioinformatics analysis and experimental verification. Genes (Basel) 9(1), pp. 10.3390/genes9010051. 2018. DOI: E51.
[5] E. Enerly, I. Steinfeld, K. Kleivi, S. K. Leivonen, M. R. Aure, H. G. Russnes, J. A. Ronneberg, H. Johnsen, R. Navon, E. Rodland, R. Makela, B. Naume, M. Perala, O. Kallioniemi, V. N. Kristensen, Z. Yakhini and A. L. Borresen-Dale. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 6(2), pp. e16915. 2011. DOI: 10.1371/journal.pone.0016915.
[6] B. D. Wang, K. Ceniccola, Q. Yang, R. Andrawis, V. Patel, Y. Ji, J. Rhim, J. Olender, A. Popratiloff, P. Latham, Y. Lai, S. R. Patierno and N. H. Lee. Identification and functional validation of reciprocal microRNA-mRNA pairings in african american prostate cancer disparities. Clin. Cancer Res. 21(21), pp. 4970-4984. 2015. DOI: 10.1158/1078-0432.CCR-14-1566.
[7] V. Ramesh and K. Ganesan. Integrative analysis of transcriptome and miRNome unveils the key regulatory connections involved in different stages of hepatocellular carcinoma. Genes Cells 21(9), pp. 949-965. 2016. DOI: 10.1111/gtc.12396.
[8] S. Lin and R. I. Gregory. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer. 15(6), pp. 321-333. 2015. DOI: 10.1038/nrc3932.
[9] X. J. Tian, H. Zhang, J. Zhang and J. Xing. Reciprocal regulation between mRNA and microRNA enables a bistable switch that directs cell fate decisions. FEBS Lett. 590(19), pp. 3443-3455. 2016. DOI: 10.1002/1873-3468.12379.
[10] A. Valinezhad Orang, R. Safaralizadeh and M. Kazemzadeh-Bavili. Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int. J. Genomics 2014pp. 970607. 2014. DOI: 10.1155/2014/970607.
[11] J. Krell, J. Stebbing, C. Carissimi, A. F. Dabrowska, A. de Giorgio, A. E. Frampton, V. Harding, V. Fulci, G. Macino, T. Colombo and L. Castellano. TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network. Genome Res. 26(3), pp. 331-341. 2016. DOI: 10.1101/gr.191759.115.
[12] C. Zhang, G. Bai, W. Zhu, D. Bai and G. Bi. Identification of miRNA-mRNA network associated with acute myeloid leukemia survival. Med. Sci. Monit. 23pp. 4705-4714. 2017. DOI: 903989.
[13] Y. Feng, Y. Xing, Z. Liu, G. Yang, X. Niu and D. Gao. Integrated analysis of microRNA and mRNA expression profiles in rats with selenium deficiency and identification of associated miRNA-mRNA network. Sci. Rep. 8(1), pp. 6601-018-24826-w. 2018. DOI: 10.1038/s41598-018-24826-w.
[14] R. Zhang, Y. Y. Jiang, K. Xiao, X. Q. Huang, J. Wang and S. Y. Chen. Candidate lncRNA-miRNA-mRNA network in predicting hepatocarcinogenesis with cirrhosis: An integrated bioinformatics analysis. J. Cancer Res. Clin. Oncol. 146(1), pp. 87-96. 2020. DOI: 10.1007/s00432-019-03090-z.
[15] M. Denis and M. G. Tadesse. Evaluation of hierarchical models for integrative genomic analyses. Bioinformatics 32(5), pp. 738-746. 2016. DOI: 10.1093/bioinformatics/btv653.
[16] J. Friedman, T. Hastie and R. Tibshirani. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw 33(1), pp. 1-22. 2010.
[17] M. Tenenhaus, A. Tenenhaus and P. J. F. Groenen. Regularized generalized canonical correlation analysis: A framework for sequential multiblock component methods. Psychometrika 2017. DOI: 10.1007/s11336-017-9573-x.
[18] M. R. Fabian, N. Sonenberg and W. Filipowicz. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79pp. 351-379. 2010. DOI: 10.1146/annurev-biochem-060308-103103.
[19] J. O'Brien, H. Hayder, Y. Zayed and C. Peng. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. (Lausanne) 9pp. 402. 2018. DOI: 10.3389/fendo.2018.00402.
[20] C. J. Stavast and S. J. Erkeland. The non-canonical aspects of MicroRNAs: Many roads to gene regulation. Cells 8(11), pp. 10.3390/cells8111465. 2019. DOI: E1465.
[21] A. A. Al-Haidari, I. Syk and H. Thorlacius. MiR-155-5p positively regulates CCL17-induced colon cancer cell migration by targeting RhoA. Oncotarget 8(9), pp. 14887-14896. 2017. DOI: 10.18632/oncotarget.14841.
[22] A. Wilczynska and M. Bushell. The complexity of miRNA-mediated repression. Cell Death Differ. 22(1), pp. 22-33. 2015. DOI: 10.1038/cdd.2014.112.
[23] K. Kitagawa, G. Nakajima, H. Kuramochi, S. I. Ariizumi and M. Yamamoto. Lymphatic vessel endothelial hyaluronan receptor-1 is a novel prognostic indicator for human hepatocellular carcinoma. Mol. Clin. Oncol. 1(6), pp. 1039-1048. 2013. DOI: 10.3892/mco.2013.167.
[24] C. Meng, X. Shen and W. Jiang. Potential biomarkers of HCC based on gene expression and DNA methylation profiles. Oncol. Lett. 16(3), pp. 3183-3192. 2018. DOI: 10.3892/ol.2018.9020.
[25] R. Chauhan and N. Lahiri. Tissue- and serum-associated biomarkers of hepatocellular carcinoma. Biomark Cancer. 8(Suppl 1), pp. 37-55. 2016. DOI: 10.4137/BIC.S34413.
[26] M. Lu, X. Kong, H. Wang, G. Huang, C. Ye and Z. He. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. Oncotarget 8(5), pp. 8775-8784. 2017. DOI: 10.18632/oncotarget.14452.
[27] A. Nagy, A. Lanczky, O. Menyhart and B. Gyorffy. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci. Rep. 8(1), pp. 9227-018-27521-y. 2018. DOI: 10.1038/s41598-018-27521-y.
[28] H. Sun, J. Song, C. Weng, J. Xu, M. Huang, Q. Huang, R. Sun, W. Xiao and C. Sun. Association of decreased expression of the macrophage scavenger receptor MARCO with tumor progression and poor prognosis in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 32(5), pp. 1107-1114. 2017. DOI: 10.1111/jgh.13633.
[29] S. A. MacParland, J. C. Liu, X. Z. Ma, B. T. Innes, A. M. Bartczak, B. K. Gage, J. Manuel, N. Khuu, J. Echeverri, I. Linares, R. Gupta, M. L. Cheng, L. Y. Liu, D. Camat, S. W. Chung, R. K. Seliga, Z. Shao, E. Lee, S. Ogawa, M. Ogawa, M. D. Wilson, J. E. Fish, M. Selzner, A. Ghanekar, D. Grant, P. Greig, G. Sapisochin, N. Selzner, N. Winegarden, O. Adeyi, G. Keller, G. D. Bader and I. D. McGilvray. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat. Commun. 9(1), pp. 4383-018-06318-7. 2018. DOI: 10.1038/s41467-018-06318-7.
[30] Q. Zhu, L. Gong, J. Wang, Q. Tu, L. Yao, J. R. Zhang, X. J. Han, S. J. Zhu, S. M. Wang, Y. H. Li and W. Zhang. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). BMC Cancer 16(1), pp. 806-016-2801-4. 2016. DOI: 10.1186/s12885-016-2801-4.
[31] C. G. Liao, L. M. Kong, P. Zhou, X. L. Yang, J. G. Huang, H. L. Zhang and N. Lu. miR-10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC, uPAR and MMPs. J. Transl. Med. 12pp. 234-014-0234-x. 2014. DOI: 10.1186/s12967-014-0234-x.
[32] S. K. Narayana, K. J. Helbig, E. M. McCartney, N. S. Eyre, R. A. Bull, A. Eltahla, A. R. Lloyd and M. R. Beard. The interferon-induced transmembrane proteins, IFITM1, IFITM2, and IFITM3 inhibit hepatitis C virus entry. J. Biol. Chem. 290(43), pp. 25946-25959. 2015. DOI: 10.1074/jbc.M115.657346.
[33] M. Zhang, Q. Liu, S. Mi, X. Liang, Z. Zhang, X. Su, J. Liu, Y. Chen, M. Wang, Y. Zhang, F. Guo, Z. Zhang and R. Yang. Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J. Immunol. 186(8), pp. 4716-4724. 2011. DOI: 10.4049/jimmunol.1002989.
[34] Y. Mano, S. Aishima, N. Fujita, Y. Tanaka, Y. Kubo, T. Motomura, A. Taketomi, K. Shirabe, Y. Maehara and Y. Oda. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiology 80(3), pp. 146-154. 2013. DOI: 10.1159/000346196.
[35] P. Yang, Q. J. Li, Y. Feng, Y. Zhang, G. J. Markowitz, S. Ning, Y. Deng, J. Zhao, S. Jiang, Y. Yuan, H. Y. Wang, S. Q. Cheng, D. Xie and X. F. Wang. TGF-beta-miR-34a-CCL22 signaling-induced treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer. Cell. 22(3), pp. 291-303. 2012. DOI: 10.1016/j.ccr.2012.07.023.
[36] N. Tsuji, S. Ishiguro, Y. Sasaki and M. Kudo. CD34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma. Dig. Dis. 31(5-6), pp. 467-471. 2013. DOI: 10.1159/000355246.
[37] J. S. Jing, H. Li, S. C. Wang, J. M. Ma, L. Q. Yu and H. Zhou. NDRG3 overexpression is associated with a poor prognosis in patients with hepatocellular carcinoma. Biosci. Rep. 38(6), pp. 10.1042/BSR20180907. Print 2018 Dec 21. 2018. DOI: BSR20180907.
[38] X. Zhang, J. Sheng, Y. Zhang, Y. Tian, J. Zhu, N. Luo, C. Xiao and R. Li. Overexpression of SCAMP3 is an indicator of poor prognosis in hepatocellular carcinoma. Oncotarget 8(65), pp. 109247-109257. 2017. DOI: 10.18632/oncotarget.22665.
[39] M. F. Li, J. J. Zeng, A. P. Pan, Y. H. Lin, H. S. Lin, R. Z. Zhang, L. Yang, Y. Zhang, Y. W. Dang and G. Chen. Investigation of miR-490-3p expression in hepatocellular carcinoma based on reverse transcription-polymerase chain reaction (RT-qPCR) and a meta-analysis of 749 cases. Med. Sci. Monit. 24pp. 4914-4925. 2018. DOI: 10.12659/MSM.908492.
[40] Y. Fang, J. L. Xue, Q. Shen, J. Chen and L. Tian. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/akt pathway in hepatocellular carcinoma. Hepatology 55(6), pp. 1852-1862. 2012. DOI: 10.1002/hep.25576.
[41] X. Liao, G. Zhu, R. Huang, C. Yang, X. Wang, K. Huang, T. Yu, C. Han, H. Su and T. Peng. Identification of potential prognostic microRNA biomarkers for predicting survival in patients with hepatocellular carcinoma. Cancer. Manag. Res. 10pp. 787-803. 2018. DOI: 10.2147/CMAR.S161334.
[42] L. Liu, H. Yue, Q. Liu, J. Yuan, J. Li, G. Wei, X. Chen, Y. Lu, M. Guo, J. Luo and R. Chen. LncRNA MT1JP functions as a tumor suppressor by interacting with TIAR to modulate the p53 pathway. Oncotarget 7(13), pp. 15787-15800. 2016. DOI: 10.18632/oncotarget.7487.
[43] Y. Wang, Q. Huang, T. Deng, B. H. Li and X. Q. Ren. Clinical significance of TRMT6 in hepatocellular carcinoma: A bioinformatics-based study. Med. Sci. Monit. 25pp. 3894-3901. 2019. DOI: 10.12659/MSM.913556.
[44] E. Chen, X. Xu, R. Liu and T. Liu. Small but heavy role: MicroRNAs in hepatocellular carcinoma progression. Biomed. Res. Int. 2018pp. 6784607. 2018. DOI: 10.1155/2018/6784607.
[45] G. Bidkhori, R. Benfeitas, M. Klevstig, C. Zhang, J. Nielsen, M. Uhlen, J. Boren and A. Mardinoglu. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc. Natl. Acad. Sci. U. S. A. 115(50), pp. E11874-E11883. 2018. DOI: 10.1073/pnas.1807305115.
[46] C. J. Lin, H. Y. Gong, H. C. Tseng, W. L. Wang and J. L. Wu. miR-122 targets an anti-apoptotic gene, bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 375(3), pp. 315-20. 2008.
[47] S. Rudraiah, X. Zhang and L. Wang. Nuclear receptors as therapeutic targets in liver disease: Are we there yet? Annu. Rev. Pharmacol. Toxicol. 56pp. 605-626. 2016. DOI: 10.1146/annurev-pharmtox-010715-103209.
[48] M. L. Tornesello, L. Buonaguro, F. Izzo and F. M. Buonaguro. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget 7(18), pp. 25087-25102. 2016. DOI: 10.18632/oncotarget.7837.
[49] Cancer Genome Atlas Research Network. Electronic address: [email protected] and Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169(7), pp. 1327-1341.e23. 2017. DOI: S0092-8674(17)30639-6.
[50] C. V. Rao, A. S. Asch and H. Y. Yamada. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis 38(1), pp. 2-11. 2017. DOI: 10.1093/carcin/bgw118.